FR3078535B1 - Composition vaccinale anti-pd-l1 - Google Patents
Composition vaccinale anti-pd-l1 Download PDFInfo
- Publication number
- FR3078535B1 FR3078535B1 FR1851895A FR1851895A FR3078535B1 FR 3078535 B1 FR3078535 B1 FR 3078535B1 FR 1851895 A FR1851895 A FR 1851895A FR 1851895 A FR1851895 A FR 1851895A FR 3078535 B1 FR3078535 B1 FR 3078535B1
- Authority
- FR
- France
- Prior art keywords
- amino acid
- sequence
- protein
- acid residues
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 11
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 9
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 9
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un polypeptide comprenant, ou constitué de : - une première séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 55 à 67 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une deuxième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 85 à 101 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une troisième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 111 à 127 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une quatrième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 138 à 156 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une cinquième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 208 à 223 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1851895A FR3078535B1 (fr) | 2018-03-05 | 2018-03-05 | Composition vaccinale anti-pd-l1 |
US16/978,953 US20210395368A1 (en) | 2018-03-05 | 2019-03-05 | Anti-pd-1 vaccine composition |
PCT/EP2019/055463 WO2019170686A1 (fr) | 2018-03-05 | 2019-03-05 | Composition vaccinale anti-pd-l1 |
EP19714323.3A EP3762402A1 (fr) | 2018-03-05 | 2019-03-05 | Composition vaccinale anti-pd-l1 |
JP2020570637A JP7560365B2 (ja) | 2018-03-05 | 2019-03-05 | 抗pd-l1ワクチン組成物 |
CN201980029949.5A CN112739711A (zh) | 2018-03-05 | 2019-03-05 | 抗pd-l1疫苗组合物 |
JP2024023145A JP2024077635A (ja) | 2018-03-05 | 2024-02-19 | 抗pd-l1ワクチン組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1851895A FR3078535B1 (fr) | 2018-03-05 | 2018-03-05 | Composition vaccinale anti-pd-l1 |
FR1851895 | 2018-03-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3078535A1 FR3078535A1 (fr) | 2019-09-06 |
FR3078535B1 true FR3078535B1 (fr) | 2024-02-09 |
Family
ID=63079997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1851895A Active FR3078535B1 (fr) | 2018-03-05 | 2018-03-05 | Composition vaccinale anti-pd-l1 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210395368A1 (fr) |
EP (1) | EP3762402A1 (fr) |
JP (2) | JP7560365B2 (fr) |
CN (1) | CN112739711A (fr) |
FR (1) | FR3078535B1 (fr) |
WO (1) | WO2019170686A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022005044A2 (pt) * | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
EP3845556A1 (fr) * | 2019-12-31 | 2021-07-07 | Peptinov SAS | Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6 |
CN112745384A (zh) * | 2021-01-15 | 2021-05-04 | 新乡学院 | 猪pd-l14qn-gf表位多肽及其应用 |
CN113072620B (zh) * | 2021-04-26 | 2022-07-05 | 南通大学 | 一种具有镇痛活性的pd-1靶向肽、其合成方法及其应用 |
WO2024048418A1 (fr) * | 2022-08-29 | 2024-03-07 | 国立大学法人北海道大学 | Anticorps anti-pd-l1 pour la détection de pd-l1 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0026334D0 (en) * | 2000-10-27 | 2000-12-13 | Smithkline Beecham Biolog | Vaccine |
EP1751186A2 (fr) | 2004-06-02 | 2007-02-14 | Cytos Biotechnology AG | Conjugues entraineurs des peptides du tnf |
US8703147B2 (en) * | 2007-11-05 | 2014-04-22 | The Walter And Eliza Hall Institute Of Medical Research | Methods and compositions for treating and preventing malaria (2) |
US9637532B2 (en) * | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
EP3092495B1 (fr) * | 2014-01-06 | 2020-11-25 | Expression Pathology, Inc. | Dosage srm pour pd-l1 |
JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
WO2016160792A1 (fr) * | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Anticorps spécifiques de la protéine pd-l1 glycosylée et leurs procédés d'utilisation |
WO2017005670A1 (fr) * | 2015-07-04 | 2017-01-12 | Evaxion Biotech Aps | Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa |
KR102418372B1 (ko) * | 2016-03-29 | 2022-07-08 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법 |
EP3446119A1 (fr) * | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Prédiction améliorée d'épitope hla |
WO2017211886A1 (fr) | 2016-06-07 | 2017-12-14 | Deutsches Krebsforschungszentrum | Amélioration de l'immunogénicité des peptides l2 de hpv |
WO2017216384A1 (fr) * | 2016-06-17 | 2017-12-21 | Evaxion Biotech Aps | Vaccination ciblant ichthyophthirius multifiliis |
-
2018
- 2018-03-05 FR FR1851895A patent/FR3078535B1/fr active Active
-
2019
- 2019-03-05 JP JP2020570637A patent/JP7560365B2/ja active Active
- 2019-03-05 CN CN201980029949.5A patent/CN112739711A/zh active Pending
- 2019-03-05 EP EP19714323.3A patent/EP3762402A1/fr active Pending
- 2019-03-05 US US16/978,953 patent/US20210395368A1/en active Pending
- 2019-03-05 WO PCT/EP2019/055463 patent/WO2019170686A1/fr unknown
-
2024
- 2024-02-19 JP JP2024023145A patent/JP2024077635A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024077635A (ja) | 2024-06-07 |
EP3762402A1 (fr) | 2021-01-13 |
US20210395368A1 (en) | 2021-12-23 |
FR3078535A1 (fr) | 2019-09-06 |
WO2019170686A1 (fr) | 2019-09-12 |
JP2021517472A (ja) | 2021-07-26 |
JP7560365B2 (ja) | 2024-10-02 |
CN112739711A (zh) | 2021-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR3078535B1 (fr) | Composition vaccinale anti-pd-l1 | |
JP2019532996A5 (fr) | ||
TR200202254T2 (tr) | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri. | |
EA200800159A1 (ru) | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) | |
NO20070296L (no) | Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner | |
WO2012046061A3 (fr) | Antigènes de clostridium difficile | |
ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon | |
JOP20210298A1 (ar) | طرق وتركيبات للوقاية من مرض السكري من النوع الأول | |
DK0690721T3 (da) | Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter | |
WO2013150309A8 (fr) | Antigènes de clostridium difficile | |
PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie | |
MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
WO2007041285A3 (fr) | Complexes de fractions inactivees de pepsines et de proteines de choc thermique | |
EP4272751A3 (fr) | Analogues de compstatine et leurs utilisations médicales | |
ATE175119T1 (de) | Vakzine gegen immunodefizienz-virus der katze (kiv) | |
EP4361177A3 (fr) | Compositions de protéines de fusion recombinées de neuréguline-1 humaine (nrg-1) et procédés d'utilisation associés | |
WO2003070176A3 (fr) | Defensines modifiees et utilisations de ces dernieres | |
WO2004112820A3 (fr) | Peptides et peptidomimetiques activite immunomodulatrice, anti-inflammatoire et antivirale | |
ATE540971T1 (de) | Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes | |
NO20060675L (no) | Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider | |
HUP0401732A2 (hu) | Kopolimerek használata aktív szerként peptidet és fehérjét tartalmazó galenikus formák előállításához | |
DE60323634D1 (de) | Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 | |
MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
FR3001729B1 (fr) | Mutants du facteur x | |
DK1504036T3 (da) | Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20190906 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |